BDO’s Life Sciences M&A team has advised the shareholders of Renascience Pharma on the sale to Lupin Healthcare (UK), subsidiary of global pharmaceutical leader, Lupin. 

Renascience Pharma is a UK-based, sole supplier of four niche branded generic medicines that cover the following therapeutic areas - infectious disease, pain management, and cardiology and nephrology.

Renascience was founded with the goal of improving patient access to specialty, critical medicines - a vision that aligns with Lupin’s product portfolio strategy. This strategic acquisition will strengthen Lupin’s branded medicine portfolio in the UK and further its commitment to patient care.

Lupin Limited is a global, listed pharmaceutical leader headquartered in Mumbai, India with products distributed in over 100 markets.

 

"Huge thanks to the BDO Life Sciences M&A team for their support and advice. Their hands-on approach and sector knowledge combined with rigorous execution allowed for a smooth process and great outcome for us and for patients.  The team were great to work with and were always willing to go above and beyond – we wouldn’t hesitate to recommend them!"
Peter Mollison, Co-Founder of Renascience Pharma